Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:11:04.202Z.
Calculation as of: 2026-10-06T14:11:04.202Z.
Quote observation: 2026-10-06T14:09:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ade6551c806a0b8a23cc3b9f653dfce73cf5104c20f92b5c51aa4b81f5201f45
PE RATIO
N/A
Market Cap
$563.35M
PE Ratio
N/A
TTM Avg
506.15
3Y Avg
506.15
5Y Avg
506.15
Market Cap
$598.37M
PE Ratio
4.74
TTM Avg
17.55
3Y Avg
51.19
5Y Avg
25.53
Market Cap
$537.16M
PE Ratio
1196.92
TTM Avg
806.49
3Y Avg
715.80
5Y Avg
715.80
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) | $572.90M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $565.64M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $563.90M | 3.37 | 5.18 | 15.60 | 15.60 |
| Aquestive Therapeutics, Inc. (AQST)vs › | $563.35M | N/A | 506.15 | 506.15 | 506.15 |
| OrthoPediatrics Corp. (KIDS)vs › | $585.02M | N/A | 419.02 | 415.26 | 415.26 |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $553.64M | N/A | 80.35 | 49.81 | 49.81 |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | 4.74 | 17.55 | 51.19 | 25.53 |
| Delcath Systems, Inc. (DCTH)vs › | $537.16M | 1196.92 | 806.49 | 715.80 | 715.80 |
| Crescent Biopharma, Inc. (CBIO)vs › | $530.42M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$19.70
Forward EPS (Est.)
$-5.54
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
